AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018

Click here to view online. Add this email to your safelist.

5 March 2018

At the American College of Cardiology (ACC) 67th Annual Scientific Session & Expo 2018, AstraZeneca will deliver industry-leading science and insights that augment the body of evidence on clinical approaches to tackling cardiovascular diseases. The Company will present 10 abstracts, three of which are accepted as ACC late breakers.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.